The UK and US have signed a landmark commercial pact that will maintain no import taxes on British medicine shipments entering the American market.
Key Provisions of the Pact
Under the terms of the agreement, the UK has committed to raise spending on medicines through the public health system. This move ensures that duties on these crucial exports will be held at zero for a duration of the next three years.
This agreement is in response to previous statements to significantly raise import taxes on patented pharmaceutical products, with potential rates mentioned up to double the cost.
"This arrangement between the UK reinforces the worldwide climate for innovative medicines and establishes long-overdue fairness to U.S.–U.K. drug exports," a release said.
Trade Significance
Medicines constitute one of the UK's largest exports to the America, which is by far the largest buyer for leading British pharmaceutical firms.
Trade data reveal that in the year leading up to September, the UK exported pharmaceutical products totaling £11.1bn to the US. This figure made up nearly one-fifth of British export trade in that span.
"This agreement protects employment, stimulates capital expenditure and facilitates the UK to establish itself as a worldwide center for biotech and pharma," a government official stated.
Specific British Pledges
The agreement entails several notable pledges from the United Kingdom:
- Revised Affordability Limit: The UK will raise the cost ceiling at which it considers new therapies to be too expensive by twenty-five percent.
- Boosted Medicine Funding: There is a target to raise total health service expenditure on treatments from 0.3% of GDP to 0.6% over the coming ten years.
- Rebate Cap: The percentage drug companies must return to the NHS to stay within budget will be restricted at 15%. In the past, refunds were more than twenty percent.
Recent Tensions
The pact comes amid a ongoing dispute between the sector and the UK government over drug pricing and NHS adoption.
The disagreement were exacerbated by claims that US consumers were paying significantly more for the identical medicines than consumers in the Britain and the EU.
Over the last 18 months, several major drug company projects in the UK have been halted or scrapped, while major investments have been announced toward US facilities.
A senior figure stated that the NHS must spend more on drugs, noting that its expenditure on drugs had shrunk as a share of its overall budget over the last ten years.